VICTORIA is the first positive outcome study focusing specifically on over 5,000 high-risk HFrEF patients following a HF hospitalization or outpatient IV diuretic use
VICTORIA: key characteristics
Phase 3, randomized, parallel-group, placebo-controlled, double-blind, event-driven, multicenter trial1
Compared VERQUVO to placebo, both added on to standard of care HF therapies
- Primary endpoint was a composite of time to CV death or HF hospitalization
- Patients were treated up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo
Median follow-up was 11 months
Included 5,050 adult patients with HFrEF:
- 84% had a HF hospitalization within 6 months of enrollment
- 16% had been treated with a IV diuretics within 3 months of enrollment
- High NT-proBNP levels: Median NT-proBNP=2,800 pg/mL2
- Low mean eGFR: 62 mL/min/1.73 m2 2
- 12% of patients had an eGFR between 15 and 30 mL/min/1.73 m2
- VERQUVO was not studied in patients with eGFR <15 mL/min/1.73 m2 at treatment initiation or who were on dialysis
- Patients were well treated: 91% of patients were treated with 2 or more HF medications
- LVEF <45%
CV = cardiovascular; eGFR = estimated glomerular filtration rate; HF = heart failure; HFH = heart failure hospitalization; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal prohormone B-type natriuretic peptide; VICTORIA = Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
1. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893.
2. Pieske B, Patel MJ, Westerhout CM, et al; on behalf of the VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail. 2019;21(12):1596-1604.